• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Warby Parker Inc.

    2/27/25 5:00:06 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email
    S-8 1 tm257754d1_s8.htm FORM S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Warby Parker Inc.

    (Exact name of Registrant as specified in its charter)

     

         
    Delaware   80-0423634

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    233 Spring Street, 6th Floor East

    New York, New York 10013

    (646) 847-7215

    (Address of principal executive offices) (Zip code)

     

    Warby Parker Inc. 2021 Incentive Award Plan

    Warby Parker Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

     

     

    Neil Blumenthal, Co-Founder and Co-Chief Executive Officer

    Dave Gilboa, Co-Founder and Co-Chief Executive Officer

    Warby Parker Inc.

    233 Spring Street, 6th Floor East

    New York, New York 10013

    (646) 847-7215

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    With copies to:

    Steven Miller
    Chris Utecht
    Lindsay Buxbaum
    Warby Parker Inc.
    233 Spring Street, 6th Floor East
    New York, New York 10013
    (646) 847-7215
     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer x   Accelerated filer ¨  
             
      Non-accelerated filer ¨     Smaller reporting company ¨  
             
          Emerging growth company ¨  

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 6,035,574 shares of Warby Parker Inc.’s (the “Registrant”) Class A common stock, $0.0001 par value per share (“Class A common stock”), to be issued pursuant to the Warby Parker Inc. 2021 Incentive Award Plan (the “2021 Plan”) and an additional 1,207,114 shares of the Registrant’s Class A common stock to be issued pursuant to the Warby Parker Inc. 2021 Employee Stock Purchase Plan (the “2021 ESPP”) and for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

     

    The contents of the Registration Statements on Form S-8 (File Nos. 333-259703, 333-263698,333-270140 and 333-277548), filed with the Securities and Exchange Commission, relating to the 2021 Plan and the 2021 ESPP, are incorporated herein by reference.

     

    Item 8. Exhibits

     

    Exhibit Number   Description
         
    4.1   Specimen Class A common stock certificate of Warby Parker Inc. (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-259035) filed on August 24, 2021)
         
    4.2   Specimen Class B common stock certificate of Warby Parker Inc. (incorporated by reference to Exhibit 4.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40825) filed on May 16, 2022)
         
    4.3   Twelfth Amended and Restated Certificate of Incorporation of Warby Parker Inc. (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-8 (File No. 333-259704) filed on September 22, 2021)
         
    4.4   Amended and Restated Bylaws of Warby Parker Inc. (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-8 (File No. 333-259704) filed on September 22, 2021)
         
    5.1*   Opinion of Latham & Watkins LLP
         
    23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
         
    23.2*   Consent of Latham & Watkins LLP (included in Exhibit 5.1)
         
    24.1*   Power of Attorney (included on signature page)
         
    99.1   Warby Parker Inc. 2021 Incentive Award Plan and related form agreements (incorporated by reference to Exhibit 10.5 to the Registrant's Annual Report on Form 10-K (File No. 001-40825) filed on February 29, 2024)
         
    99.2   Warby Parker Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K (File No. 001-40825) filed on February 29, 2024)
         
    107.1*   Filing Fee Table

     

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on February 27, 2025.

      WARBY PARKER INC.
       
      By: /s/ Neil Blumenthal
        Neil Blumenthal
        Co-Chief Executive Officer
       
      By: /s/ Dave Gilboa
        Dave Gilboa
        Co-Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Neil Blumenthal, Dave Gilboa, and Steven Miller, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Neil Blumenthal   Co-Chief Executive Officer and Director
    (Co-Principal Executive Officer)
      February 27, 2025
    Neil Blumenthal        
             
    /s/ Dave Gilboa   Co-Chief Executive Officer and Director
    (Co-Principal Executive Officer)
      February 27, 2025
    Dave Gilboa        
             
    /s/ Steven Miller   Chief Financial Officer   February 27, 2025
    Steven Miller   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Andrew Hunt   Director   February 27, 2025
    Andrew Hunt        
             
    /s/ Jeffrey Raider   Director   February 27, 2025
    Jeffrey Raider        
             
    /s/ Teresa Briggs   Director   February 27, 2025
    Teresa Briggs        
             
    /s/ Joel Cutler   Director   February 27, 2025
    Joel Cutler        
             
    /s/ Youngme Moon   Director   February 27, 2025
    Youngme Moon        
             
    /s/ Bradley Singer   Director   February 27, 2025
    Bradley Singer        
             
    /s/ Ronald A. Williams   Director   February 27, 2025
    Ronald A. Williams        

     

     

     

    Get the next $WRBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    12/10/2025$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    11/7/2025$28.00 → $24.00Outperform
    Telsey Advisory Group
    8/1/2025$22.00 → $28.00Outperform
    Telsey Advisory Group
    7/10/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    More analyst ratings

    $WRBY
    SEC Filings

    View All

    Warby Parker Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Warby Parker Inc. (0001504776) (Filer)

    2/9/26 4:19:28 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Warby Parker Inc.

    SCHEDULE 13G/A - Warby Parker Inc. (0001504776) (Subject)

    1/23/26 11:08:18 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form 144 filed by Warby Parker Inc.

    144 - Warby Parker Inc. (0001504776) (Subject)

    1/13/26 4:21:45 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Warby Parker Appoints Adrian Mitchell as Chief Financial Officer

    Warby Parker Inc. (NYSE:WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment strengthens Warby Parker's leadership team as the company continues executing its strategic vision, building on a track record of retail and product innovation while expanding into new categories, including the launch of its first AI glasses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209259218/en/Adrian Mitchell, Chief Financial Officer Mitchell has more than 25 years of experience leading some of the worl

    2/9/26 4:10:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

    Warby Parker Inc. (NYSE: WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 3:00 p.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com. An online archive will be available for a period of 90 days following the presentation. About Warby Parker Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-

    11/26/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Warby Parker upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Warby Parker from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    12/10/25 9:45:30 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $24.00 from $28.00 previously

    11/7/25 7:48:31 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $28.00 from $22.00 previously

    8/1/25 8:16:04 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Blumenthal Neil Harris sold $19,793 worth of shares (660 units at $29.99) and converted options into 660 shares (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/15/26 6:36:33 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Gilboa David Abraham converted options into 80,094 shares and sold $2,359,569 worth of shares (80,094 units at $29.46) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/15/26 6:35:24 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Gilboa David Abraham converted options into 94,906 shares and sold $2,610,816 worth of shares (94,906 units at $27.51) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/9/26 8:48:36 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    8/14/24 4:52:02 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    View All

    Warby Parker Appoints Adrian Mitchell as Chief Financial Officer

    Warby Parker Inc. (NYSE:WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment strengthens Warby Parker's leadership team as the company continues executing its strategic vision, building on a track record of retail and product innovation while expanding into new categories, including the launch of its first AI glasses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209259218/en/Adrian Mitchell, Chief Financial Officer Mitchell has more than 25 years of experience leading some of the worl

    2/9/26 4:10:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Monumental Sports & Entertainment Appoints Corporate Finance Executive Steven Miller as Executive Vice President and Chief Financial Officer

    Steven Miller, currently Chief Financial Officer and Treasurer of Warby Parker (NYSE: WRBY), has been appointed Chief Financial Officer of Monumental Sports & Entertainment, effective October 2, 2025, and will join the Senior Executive Leadership TeamAs previously announced, after an extraordinary 25-year career at Monumental Sports & Entertainment, Peter Biché transitioned from Chief Financial Officer to Senior Advisor WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE), one of the nation's leading integrated sports, media, and entertainment companies, announced that Steven (Steve) Miller will become its Executive Vice President and Chief Financial Officer (CFO

    9/9/25 6:30:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

    8/1/24 4:15:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 5:08:23 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 1:30:16 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/12/24 10:40:28 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Financials

    Live finance-specific insights

    View All

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before market open on November 6, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 958403. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where p

    10/16/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Second Quarter 2025 Results

    Net revenue increased 14% year over year to $214 million; Raises outlook Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2025. "It has been a busy and exciting year marked by major milestones. We celebrated opening our 300th store and distributing 20 million pairs of glasses to people in need around the world. Looking ahead, our partnership with Google to develop intelligent eyewear is a testament to Warby Parker's commitment to innovation as we shape the future of how people

    8/7/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care